Drug Trial Radar · NCT00500682
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,020
Actual
Start
Jul 2007
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Kureha Corporation
- First posted
- Jul 13, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function.
Conditions
- Chronic Kidney Disease
Interventions
PlaceboDrug
9g /day (3 times a day)
AST-120Drug
9g /day (3 times a day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.Time frame: Beyond Week 48, a 12-week visit cycle continued until the end of the study or until individual patients reached an endpoint
- Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse EventsTime frame: Approximately 42 months
Locations
105 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Alhambra, California
Site not named
Covina, California
Site not named
Glendale, California
Site not named
Los Angeles, California
Site not named
Stamford, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Hudson, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Pembroke Pines, Florida
Site not named
Spring Hill, Florida
Site not named
Tampa, Florida
Site not named
Winter Park, Florida
Site not named
Kansas City, Kansas
Site not named
New Orleans, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Ypsilanti, Michigan
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Camden, New Jersey
Site not named
Eatontown, New Jersey
Site not named
Port Washington, New York
Site not named
Springfield Gardens, New York
Site not named
Asheville, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Dayton, Ohio
Site not named
Toledo, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Rock Hill, South Carolina
Site not named
Nashville, Tennessee
Site not named
Arlington, Texas
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Appleton, Wisconsin
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.